therapeutic

T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is an immune receptor that plays a key role in suppressing T-cell activation and proliferation. As a newly identified checkpoint, it is highly expressed on various immune cells, including CD4+ and CD8+ T cells, NK cells.

High-throughput antibody expression drives speed and scale. Biointron applies automated platforms to deliver reproducible antibodies for research and therapy.

Antibody therapeutics power modern medicine. Biointron reviews monoclonals, bispecifics, and next-gen formats advancing treatment across multiple diseases.

The COVID-19 pandemic has reshaped global health strategies, pushing preventive measures to the forefront of public attention. Now, there is a renewed focus on fortifying defenses against future viral threats and ways to improve hospitalization rates. Here, we will explore the latest advancements in post-pandemic prevention strategies and the broader landscape of public health.

Explore the role of bispecific antibodies (bsAbs) in cancer therapy and beyond, and learn how dual-targeting enhances immune responses and overcomes monoclonal limits.

News from the IASLC 2024 World Conference on Lung Cancer (WCLC24) has provided several updates on the clinical trial space for non-small cell lung cancer (NSCLC), with several antibody-based drugs at the forefront. NSCLC is the most common type of lung cancer, accounting for about 85% of all cases.

FcRn is critical for IgG recycling and half-life extension. Biointron explores its biology and applications in designing durable therapeutic antibodies.

In August, the US FDA approved Galderma’s Nemluvio (nemolizumab) for adult patients living with prurigo nodularis (PN). Nemluvio is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31, a neuroimmune cytokine that drives multiple disease mechanisms in (PN). Prurigo nodularis is a chronic skin condition that affects approximately 181,000 patients in the United States

Anti-drug antibodies (ADAs) are immune system proteins that can develop in response to therapeutic drugs, particularly biologics like monoclonal antibodies. These biopharmaceuticals have significantly advanced therapies for cancer and autoimmune diseases, but their long-term use can elicit immunogenicity due to repeated administration. The host immune system may recognize epitopes in the biologic drug as foreign, triggering the production of ADAs. This can lead to the formation of drug–ADA immune complexes, which accelerate drug clearance and potentially neutralize the drug's efficacy.

Learn the difference between ADC biosimilars as cost-effective alternatives to reference drugs and ADC isotypes engineered for distinct therapeutic properties in cancer treatment.

BIO Asia 2024 in Taiwan featured breakthroughs in biotech and antibodies. Biointron shares key takeaways that define trends in global biologics and innovation.

This month provided not just one, but two FDA approvals for antibody drugs treating patients with paroxysmal nocturnal hemoglobinuria (PNH)!

Antibody-drug conjugates unite antibody precision with cytotoxic potency. Biointron explains how ADCs deliver targeted therapies that revolutionize cancer treatment.

Healthspan and lifespan research are two distinct but interconnected areas in aging studies. Lifespan research aims to extend the total number of years an individual lives, seeking interventions that can delay the onset of age-related diseases and prolong life itself. In contrast, healthspan researc

Therapeutic antibodies have transformed modern medicine. Biointron reviews their evolution, clinical applications, and impact on shaping today’s treatment landscape.